Status:
TERMINATED
Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis
Lead Sponsor:
Kadmon, a Sanofi Company
Conditions:
Diffuse Cutaneous Systemic Sclerosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This was a phase 2, open-label, single-cohort, multicenter trial of belumosudil in participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc). An estimated total of 12 to 15 participants would rec...
Detailed Description
The primary objective of this phase 2, open-label, single-cohort, multicenter trial was to evaluate the efficacy of belumosudil 200 mg BID using the Combined Response Index in diffuse cutaneous System...
Eligibility Criteria
Inclusion
- Male and female participants greater than or equal to (\>=) 18 years old with the diagnosis of dcSSc according to the 2013 American College of Rheumatology and European League Against Rheumatism.
- Had disease duration (defined as interval from first non Raynaud disease manifestation) of less than or equal to (\<=) 6 years.
- Had mRSS of \>=15 but \<=40.
- Had active disease as determined by the Principal Investigator within the 6 months prior to screening.
- Adequate organ and bone marrow functions evaluated during the 28 days prior to enrollment as follows:
- Absolute neutrophil count \>= 1.5\*10\^9/L
- Platelet count \>= 100\*10\^9/L
- Total bilirubin \<= 1.0\*upper limit of normal (ULN)
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and serum creatinine \<= 1.5\*ULN.
- Female participants of childbearing potential had a negative pregnancy test at screening. Females of childbearing potential were defined as sexually mature women without prior hysterectomy or who had any evidence of menses in the past 12 months. However, women who had been amenorrheic for 12 or more months were still considered to be of childbearing potential if the amenorrhea was possibly due to prior chemotherapy, anti-estrogens, or ovarian suppression.
- Women of childbearing potential (i.e., menstruating women) must had a negative urine pregnancy test (positive urine tests were to be confirmed by serum test) documented within the 24-hour period prior to the first dose of study drug.
- Sexually active women of childbearing potential enrolled in the study agreed to use two forms of accepted methods of contraception during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes (i) intrauterine device plus 1 barrier method; (ii) on stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus 1 barrier method; or (iii) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm), or a vasectomized partner.
- For male participants who were sexually active and who were partners of premenopausal women: agreement to use 2 forms of contraception as in criterion number 6b above during the treatment period and for at least 3 months after the last dose of study drug.
- Male participants must not donate sperm for 3 months after last dose of study drug.
- Able to provide written informed consent prior to the performance of any study-specific procedures.
Exclusion
- Participants had corrected QT interval using Fridericia's formula (QTcF) greater than 450 milliseconds.
- Ongoing use or current use of concomitant medication known to have the potential for QTc prolongation.
- Female participant who was pregnant or breastfed.
- Participated in another study with an investigational drug within 28 days of study entry (for studies involving biologics, within 3 half-lives of the biologic).
- History or other evidence of severe illness or any other conditions that would make the participant, in the opinion of the Investigator, unsuitable for the study.
- Chronic heart failure with New York Heart Association Classes II, III, or IV.
- Acute or chronic liver disease (e.g., cirrhosis).
- Positive human immunodeficiency virus (HIV) test.
- Active hepatitis C virus (HCV), hepatitis B virus (HBV), or positive whole blood tuberculin test.
- Diagnosed with any malignancy within 3 years of enrollment, with the exception of basal cell or completely resected squamous cell carcinoma of the skin, resected in situ cervical malignancy, resected breast ductal carcinoma in situ, or low risk prostate cancer after curative resection.
- Had previous exposure to belumosudil or known allergy/sensitivity to belumosudil, or any other Rho-associated Protein Kinase-2 (ROCK2) inhibitor.
- Scleroderma renal crisis within 4 months prior to enrollment.
- Forced vital capacity \<= 50% Predicted.
Key Trial Info
Start Date :
March 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 19 2022
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04680975
Start Date
March 3 2021
End Date
December 19 2022
Last Update
June 5 2023
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Los Angeles Medical Center_Site number 104
Los Angeles, California, United States, 90095
2
Yale University School of Medicine_Site number 140
New Haven, Connecticut, United States, 06519
3
Northwestern University_Site number 124
Chicago, Illinois, United States, 60611
4
Columbia University Medical Center_Site number 086
New York, New York, United States, 10032